Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2015 May 13

PMID 25963079

Citations 4

Authors

Cheng Wu

Lijie Liu

Peng Zhao

Dan Tang

Dingkang Yao

Liang Zhu

Zhiqiang Wang

Affiliations

Soon will be listed here.

Abstract

Background/aims: To screen for serum protein/peptide biomarkers of hepatitis B virus (HBV)-associated chronic hepatic lesions in an attempt to profile the progression of HBV-associated chronic hepatic lesions using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) techniques.

Methods: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers. The most valuable SELDI peak for predicting the progression to LC in HBV-infected patients was identified.

Results: A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen a-chain precursor, isoform 1.

Conclusions: The peptide of the C-terminal fraction of the fibrinogen α-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.

Citing Articles

Identification and validation of plasma AGRN as a novel diagnostic biomarker of hepatitis B Virus-related chronic hepatitis and liver fibrosis/cirrhosis.

Ai R, Li L, Yuan X, Zhao D, Miao T, Guan W Histol Histopathol. 2024; 39(8):1025-1035.

PMID: 38197199 DOI: 10.14670/HH-18-695.

Proteomics approach to identify serum biomarkers associated with the progression of diabetes in Korean patients with abdominal obesity.

Kim S, Choi J, Yun J, Chung I, Cho H, Song S PLoS One. 2019; 14(9):e0222032.

PMID: 31504048 PMC: 6736247. DOI: 10.1371/journal.pone.0222032.

Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Jeong S, Tong Y, Sha M, Gu J, Xia Q Oncotarget. 2016; 8(10):17292-17300.

PMID: 28030846 PMC: 5370041. DOI: 10.18632/oncotarget.14079.

Identification of carboxyl terminal peptide of Fibrinogen as a potential serum biomarker for gastric cancer.

Wu C, Luo Z, Tang D, Liu L, Yao D, Zhu L Tumour Biol. 2015; 37(5):6963-70.

PMID: 26662807 DOI: 10.1007/s13277-015-4394-y.

References

Ogata Y, Heppelmann C, Charlesworth M, Madden B, Miller M, Kalli K . Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res. 2006; 5(12):3318-25. DOI: 10.1021/pr060344+. View

Zheng G, Wang C, Qu X, Deng X, Deng B, Zhang J . Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol. 2007; 28(4):282-7. View

Poon T . Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics. 2007; 4(1):51-65. DOI: 10.1586/14789450.4.1.51. View

Vlahou A, Schellhammer P, Mendrinos S, Patel K, Kondylis F, Gong L . Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001; 158(4):1491-502. PMC: 1891900. DOI: 10.1016/S0002-9440(10)64100-4. View

Rosty C, Christa L, Kuzdzal S, Baldwin W, Zahurak M, Carnot F . Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002; 62(6):1868-75. View

Lok A . Chronic hepatitis B. N Engl J Med. 2002; 346(22):1682-3. DOI: 10.1056/NEJM200205303462202. View

Adam B, Qu Y, Davis J, Ward M, Clements M, Cazares L . Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62(13):3609-14. View

Torbenson M, Thomas D . Occult hepatitis B. Lancet Infect Dis. 2002; 2(8):479-86. DOI: 10.1016/s1473-3099(02)00345-6. View

Tang N, Tornatore P, Weinberger S . Current developments in SELDI affinity technology. Mass Spectrom Rev. 2003; 23(1):34-44. DOI: 10.1002/mas.10066. View

10.

Lavanchy D . Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2):97-107. DOI: 10.1046/j.1365-2893.2003.00487.x. View

11.

Rocken C, Ebert M, Roessner A . Proteomics in pathology, research and practice. Pathol Res Pract. 2004; 200(2):69-82. DOI: 10.1016/j.prp.2004.03.002. View

12.

Poniachik J, Bernstein D, Reddy K, Jeffers L, Civantos F, Schiff E . The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996; 43(6):568-71. DOI: 10.1016/s0016-5107(96)70192-x. View

13.

Huang S, Cao Z, Chung D, Davie E . The role of betagamma and alphagamma complexes in the assembly of human fibrinogen. J Biol Chem. 1996; 271(44):27942-7. DOI: 10.1074/jbc.271.44.27942. View

14.

Poon T, Hui A, Chan H, Ang I, Chow S, Wong N . Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem. 2004; 51(2):328-35. DOI: 10.1373/clinchem.2004.041764. View

15.

Schwegler E, Cazares L, Steel L, Adam B, Johnson D, John Semmes O . SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. 2005; 41(3):634-42. DOI: 10.1002/hep.20577. View

16.

Lavanchy D . Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2006; 34 Suppl 1:S1-3. DOI: 10.1016/s1386-6532(05)00384-7. View

17.

Theodorescu D, Wittke S, Ross M, Walden M, Conaway M, Just I . Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006; 7(3):230-40. DOI: 10.1016/S1470-2045(06)70584-8. View

18.

Engwegen J, Gast M, Schellens J, Beijnen J . Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci. 2006; 27(5):251-9. DOI: 10.1016/j.tips.2006.03.003. View

19.

Bouamrani A, Ternier J, Ratel D, Benabid A, Issartel J, Brambilla E . Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin Chem. 2006; 52(11):2103-6. DOI: 10.1373/clinchem.2006.070979. View

20.

Su Y, Shen J, Qian H, Ma H, Ji J, Ma H . Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci. 2006; 98(1):37-43. PMC: 11158238. DOI: 10.1111/j.1349-7006.2006.00339.x. View